Table 1. Comparisons of clinical and molecular features in AML patients with and without IDH1/2 mutations.
| Variable | IDH1/2 WT | IDH1/2 mutations | P-value |
|---|---|---|---|
| Age, median(range), yrs | 47(14,82) | 57(15,78) | <0.001 |
| Percent blast, median(range) | 65(20,98) | 73(20,97) | 0.15 |
| WBC, median(range),10^9/L | 11(0.2,487) | 14(0.4,262) | 0.50 |
| Female, n(%) | 114(41) | 32(38) | 0.60 |
| FAB classification, n(%) | <0.001 | ||
| M0 | 15(5) | 18(21) | |
| M1 | 19(7) | 7(8) | |
| M2 | 93(33) | 29(34) | |
| M4 | 56(20) | 6(7) | |
| M5 | 90(32) | 22(26) | |
| M6 | 6(2) | 3(4) | |
| Cytogenetic subtype, n(%) | 0.04 | ||
| Favorable | 30(11) | 2(2) | |
| Intermediate | 211(76) | 70(82) | |
| Adverse | 38(14) | 13(15) | |
| Gene mutations, n(%) | |||
| FLT3ITD | 41(15) | 16(19) | 0.36 |
| NPM1 | 60(22) | 29(34) | 0.02 |
| CEBPA DM | 25(9) | 2(2) | 0.04 |
| DNMT3a | 29(10) | 15(18) | 0.07 |
WT: wild type; WBC: white blood cell counts; FAB: French-America-British; DM: double-allele.